Hölderle-Carré Apotheke Caunes

The site focuses on HER2+ early breast cancer, a subtype of neoplasms where innovative neoadjuvant treatment strategies are being evaluated to improve outcomes.

• Safety monitoring of new antibody‑drug conjugates
• Assessment of pathological complete response (pCR)
• Long‑term disease‑free survival
• Comparison with standard chemotherapy regimens
• Personalized therapy based on dynamic biomarkers

Researchers at Hölderle‑Carré Apotheke Caunes aim to demonstrate that T‑DXd–based regimens can safely replace conventional options, potentially setting a new standard for early‑stage disease management.

Clinical work at the pharmacy also targets triple‑negative early breast cancer, a high‑risk form of neoplasms where novel immunotherapy combinations are under investigation.

• Evaluation of immune checkpoint inhibition with chemotherapy
• Measurement of pathological complete response (pCR)
• Three‑year invasive disease‑free survival rates
• Safety profile of combined antibody‑drug conjugates
• Risk‑adapted treatment for low‑recurrence patients

The trial seeks to prove that adding pembrolizumab to sacituzumab govitecan can boost efficacy while maintaining an acceptable safety margin, offering a new option for patients with limited alternatives.